Refine
Has Fulltext
- yes (21)
Is part of the Bibliography
- yes (21)
Document Type
- Journal article (21)
Language
- English (21) (remove)
Keywords
- multiple myeloma (13)
- refractory (4)
- relapse (4)
- 18F-FDG PET/CT (2)
- Multiple myeloma (2)
- daratumumab (2)
- extramedullary disease (2)
- immunotherapy (2)
- 11C-Methionine PET/CT (1)
- 68Ga-Pentixafor PET/CT (1)
Institute
- Medizinische Klinik und Poliklinik II (21)
- Klinik und Poliklinik für Nuklearmedizin (6)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (4)
- Pathologisches Institut (4)
- Theodor-Boveri-Institut für Biowissenschaften (2)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (1)
- Institut für Informatik (1)
- Institut für Virologie und Immunbiologie (1)
- Lehrstuhl für Orthopädie (1)
Sonstige beteiligte Institutionen
The treatment landscape in multiple myeloma (MM) is shifting from genotoxic drugs to immunotherapies. Monoclonal antibodies, immunoconjugates, T-cell engaging antibodies and CART cells have been incorporated into routine treatment algorithms, resulting in improved response rates. Nevertheless, patients continue to relapse and the underlying mechanisms of resistance remain poorly understood. While Impaired death receptor signaling has been reported to mediate resistance to CART in acute lymphoblastic leukemia, this mechanism yet remains to be elucidated in context of novel immunotherapies for MM. Here, we describe impaired death receptor signaling as a novel mechanism of resistance to T-cell mediated immunotherapies in MM. This resistance seems exclusive to novel immunotherapies while sensitivity to conventional anti-tumor therapies being preserved in vitro. As a proof of concept, we present a confirmatory clinical case indicating that the FADD/BID axis is required for meaningful responses to novel immunotherapies thus we report impaired death receptor signaling as a novel resistance mechanism to T-cell mediated immunotherapy in MM.